Nuclea Biotechnologies, the Pittsfield, MA-based developer of genomic tests for cancer research, has raised $3.4 million in new equity financing, according to a regulatory filing. The company, which says on its website that it has collaborations with the Dana-Farber Cancer Institute in Boston and the Johns Hopkins School of Medicine in Baltimore, is seeking to discover genomic signatures that could lead to better diagnosis and prognosis for cancer patients. The company said in July it has closed on a $1 million private placement.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
